PlantForm Corporation



Annual General Meeting September 21, 2010

Dr. Don Stewart President and CEO +1 (416) 452 7242 don.stewart@plantformcorp.com



©PlantForm Corporation 2010

www.plantformcorp.com

The Opportunity





The introduction of more affordable, biosimilar versions of already approved treatments is a priority for health care providers to reduce costs and increase the availability of life-saving medicines.

The Opportunity





- PlantForm uses its proprietary platform to produce drugs at ultra-low cost in plants.
- PlantForm's current and future products are manufactured at only 5% to 10% of the cost of name-brand equivalents.
- PlantForm's first product is biosimilar Herceptin, a \$5.0 billion/year breast cancer drug.

Use of Funds



Туре	Investors	Amount (Millions)	Milestones	Time	Value (Millions)
Round 1	Angels Early-stage VC Government	\$1.5 (\$1M raised to date)	Demonstrate Cost of Goods Efficacy study	Year 1	\$4-6
Round 2	Institutional investors Government	\$5.0	Manufacturing for Phase I IND package IND submission Phase I clinical trial	Year 2	\$50 Exit 1
Round 3	Institutional investors	\$27.0	Manufacturing for Phase III GMP process validation	Year 4	\$250
	Partner	\$45.0	Phase III clinical trial License submission		Exit 2

IND = Investigational New Drug application

Innovation Award



2010 Innovator of the Year Award

^{from} Guelph Partnership for Innovation



Guelph, Ontario, Canada





Current Status

• Biosimilar Herceptin product

- Laboratory production process established:
 - Produced in tobacco plants
 - Purified from tobacco plants
- Equivalency of PlantForm biosimilar to name-brand drug established:
 - Identity
 - Activity in vitro
 - Molecular size
 - Molecular forms
 - Binding to HER2 receptor target
 - Amino acid sequence (amino terminus)

Current Technical Objectives



• Primary

- Manufacturing gram quantities of biosimilar Herceptin
- Conduct animal efficacy study in mice (*in vivo* comparison of PlantForm biosimilar to Herceptin)

• Secondary

- Develop transgenic plants for improved performance
- Develop modified glycosylation host plants



Recent Advances

- Manufacturing gram quantities of biosimilar Herceptin
 - Preclinical manufacturing strategy defined
 - Upstream (greenhouse) and downstream (GMP) manufacturing CMO
 - Contract in place with KBP (Kentucky, USA)
 - Work initiated in Q3, 2010
 - Fill/Finish manufacturing CMO
 - $\circ~$ Scope of work being defined



Recent Advances

• Platform development

- Evaluating novel Protein A capture technology
- Increased expression rates x4
- Cloned improved expression vector system (anticipated 5-10 fold increase in product)
- o Developed modified glycosylated tobacco plants



Patent Status

• Core platform technology

- "Methods of Improving the Therapeutic Efficacy and Utility of Antibody Fragments"
- PCT Search and Opinion, "all claims novel and inventive" (Feb. 2010)
- o International Application published No. WO 2010/051635 A1 (May 2010)

• Innovative drug candidate

- o "Anti-Cobra Toxin Antibody Fragments"
- PCT Application No. PCT/CA2009/001760 (December, 2009)
- PCT Search and Opinion (April, 2010)

Biosimilar Herceptin manufacturing process

- "Production of HER Receptor Antibodies in Plant"
- o US Provisional Application No. 61/355,300 (June 2010)

Financing Advances



- **Finance** (\$1M raised to date towards \$1.5M target)
 - Angel financing
 - \$800,000 raised
 - Government
 - \$200,000 committed from the Syndicated Investment Fund

Institutional

- Ongoing positive discussions
- PlantForm information being exchanged

Scientific Advisory Board



Chris Hall, PhD (Chair) University of Guelph & CSO PlantForm

Doug Cossar, PhD Structural Genomics Consortium

Malcolm Devine, PhD bioQED Strategic Consultants

John Hassel, PhD McMaster University

Ken Hughes, PhD Microbix Biosystems, Toronto

Steve Narod, MD Woman's College Hospital, Toronto

Steven Rothstein, PhD

Elastin Specialties & University of Guelph

©PlantForm Corporation 2010

www.plantformcorp.com




Scientific founder



Process expert

Plant







Process expert



Clinical expert



Plant expert

Board of Directors



Mark Goldberg, PhD, Board Chair, Director R&D, MTE

- PlantForm Founder, Founder of GlobalTox international consulting
- Many years of success in drug approval processes

Jim Rae, CEO, Viron Therapeutics

- Extensive public and private board experience
- Turnaround CEO for small to large biotech enterprises

Warren Whitehead, former CFO Arius Research

- Experienced adding and realizing value in biotechs
- Sold Arius Research at preclinical stage for \$200 million

Chris Hall, PhD, PlantForm Founder & Chief Scientific Officer

 Canada Research Chair in Recombinant Antibody Technology at the University of Guelph

Don Stewart, PhD, President & CEO

- PlantForm Founder
- Founder and President of Alba Biologics Group
















Communications Advances

- Quarterly Update investor reports
- Investor brochure
- New website
 - Launched September 2010



Current Technical Objectives





PlantForm Corporation



For more information, please contact:

Dr. Don Stewart President and CEO don.stewart@plantformcorp.com (416) 452-7242 www.plantformcorp.com

